Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC (GSK)

161
Delayed Quote. Delayed London Stock Exchange - 11/24 04:00:15 am
1476.5 GBp   -0.34%
24m ago GSK shareholders to vote on Novartis deal on Dec. 18
28m ago GSK shareholders to vote on Novartis deal on December 18
6d ago Exclusive - Takata retains prominent lawyer Levander in air bag scandal
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201120122013201420152016
Sales27 38726 43126 50523 19324 67625 439
Operating income (EBITDA)10 2319 4158 8837 8118 0728 470
Operating profit (EBIT)8 5548 3308 0156 4706 7597 106
Pre-Tax Profit (EBT)7 6986 6926 6474 8705 4145 959
Net income5 2614 5655 6283 2143 5823 935
EPS (PNC)10391,511170,986,279,5
Dividend per Share (PNC)70,074,078,079,880,882,5
Yield4,72%4,99%5,26%5,39%5,46%5,57%
Announcement Date02/07/2012
12:00pm
02/06/2013
12:01pm
02/05/2014
12:00pm
---
Finances - Leverage
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201120122013201420152016
Debt9 00314 03712 64513 16311 39311 361
Finance------
Operating income (EBITDA)10 2319 4158 8837 8118 0728 470
Leverage
(Debt/EBITDA)
0,88x1,49x1,42x1,69x1,41x1,34x
Capital Expenditure9231 0511 1881 3931 6581 447
Book Value Per Share (BVPS)162 PNC120 PNC146 PNC135 PNC137 PNC142 PNC
Cash Flow per Share124 PNC87,7 PNC149 PNC108 PNC115 PNC134 PNC
Announcement Date02/07/2012
12:00pm
02/06/2013
12:01pm
02/05/2014
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2014 Thomson Reuters
Advertisement
Financial Ratios

Size 2014e 2015e
Capitalization 72 012 M GBP -
Entreprise Value (EV) 85 175 M GBP 83 405 M GBP
Valuation 2014e 2015e
PER (Price / EPS) 20,9x 17,2x
Capitalization / Revenue 3,10x 2,92x
EV / Revenue 3,67x 3,38x
EV / EBITDA 10,9x 10,3x
Yield (DPS / Price) 5,39% 5,46%
Profitability 2014e 2015e
Operating Margin (EBIT / Sales) 27,9% 27,4%
operating Leverage (Delta EBIT / Delta Sales) -1,54x 0,70x
Net Margin (Net Profit / Revenue) 13,9% 14,5%
ROA (Net Profit / Asset) 8,80% 9,00%
ROE (Net Profit / Equities) 60,9% 69,9%
Rate of Dividend 113% 93,7%
Balance Sheet Analysis 2014e 2015e
CAPEX / Sales   6,01% 6,72%
Cash Flow / Sales (Taux d'autofinancement) 22,6% 22,7%
Capital Intensity (Assets / Sales) 1,57x 1,61x
Financial Leverage (Net Debt / EBITDA) 1,69x 1,41x
Price Earning Ratio
EPS & Dividend
Dynamic quotes  
ON
| OFF